Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients (Q35154233)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

based on heuristic

inferred from title

Henry Seth Friedman

5

object named as

Henry S Friedman

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

David A Reardon

1

object named as

David A Reardon

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Timothy F. Cloughesy

3

object named as

Timothy Cloughesy

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Charles A Conrad

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michael D Prados

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Kenneth D Aldape

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Paul Mischel

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jane Xia

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Clifford DiLea

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jerry Huang

10

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

William Mietlowski

11

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Margaret Dugan

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Wei Chen

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

W K Alfred Yung

14

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

7 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1507-1518

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

https://scigraph.springernature.com/pub.10.1007/s00280-012-1854-6

0 references

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

A network model of a cooperative genetic landscape in brain tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Next generation oncology drug development: opportunities and challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

An integrated genomic analysis of human glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Long-term survival with glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

13 July 2018

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1854-6

21 January 2018

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1854-6

21 January 2018

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1854-6

21 January 2018

Phase II trial of gefitinib in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1854-6

21 January 2018

Optimal two-stage designs for single arm phase II cancer trials.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1854-6

21 January 2018

Application of a new multinomial phase II stopping rule using response and early progression.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1854-6

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1854-6

21 January 2018

Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1854-6

21 January 2018

Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1854-6

21 January 2018

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1854-6

21 January 2018

Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

27 September 2018

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4351868

27 September 2018

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/22392572

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-012-1854-6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

release_lzbaau6w6rft3oqkmgalv4vfxu

1 reference

https://api.fatcat.wiki/v0/release/lzbaau6w6rft3oqkmgalv4vfxu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35154233&oldid=1861545320"